zinc finger protein 260Genealiases: OZRF1 · ZFP260
Q-omics provides the consensus-scored ZNF260 profile across patient tissues and cancer cell-line models. ZNF260 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF260 is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, ZNF260 RNA expression shows 21,003 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, BLCA, and KIRP as cancer lineages where ZNF260 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF260 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF260 survival associations across molecular data types. ZNF260 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF260 RNA expression–survival associations across cancer types. High ZNF260 expression shows unfavorable associations in LIHC, MESO and LGG, but favorable associations in KIRC, HNSC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF260 RNA expression.
This table summarizes ZNF260 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF260. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF260 shows lower tumor expression in THCA and KICH and higher tumor expression in BLCA, LUAD, LIHC and BRCA. The BLCA box plot shows higher ZNF260 RNA expression in tumor versus normal tissue (log2 FC = +0.926, t-test p < 0.001).
This table shows molecular features associated with ZNF260 in patient tissues and cancer cell lines. In patient samples, ZNF260 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF260 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
